Dysfunctional pro-ceramide, ER stress, and insulin/IGF signaling networks with progression of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 30, Issue SUPPL.2, 2012, Pages

  De La Monte, Suzanne M ^a   Re, Edward ^a   Longato, Lisa ^a   Tong, Ming ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; central nervous system; ceramide; ER stress; human; insulin resistance; neurodegeneration; neurons; postmortem brain

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CERAMIDE; INSULIN; SOMATOMEDIN;

ALZHEIMER DISEASE; ARTICLE; BIOACCUMULATION; BIOSYNTHESIS; BRAIN DEGENERATION; BRAIN LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; ENDOPLASMIC RETICULUM STRESS; GENE ACTIVATION; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMAN; HUMAN TISSUE; HYPOTHESIS; INSULIN RESISTANCE; LIPID METABOLISM; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UNFOLDED PROTEIN RESPONSE; UPREGULATION;

EID: 84862892661     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-111728     Document Type: Article

References (59)

1. de la Monte SM (2012) Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease. Front Biosci E4, 1582-1605.
2. de la Monte SM, Longato L, Tong M, Wands JR (2009) Insulin resistance and neurodegeneration: Roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs 10, 1049-1060.
3. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM (2005) Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: Link to brain reductions in acetyl-choline. J Alzheimers Dis 8, 247-268.
4. Kao Y, Youson JH, Holmes JA, Al-Mahrouki A, Sheridan MA (1999) Effects of insulin on lipid metabolism of larvae and metamorphosing landlocked sea lamprey, Petromyzon marinus. Gen Comp Endocrinol 114, 405-414. (Pubitemid 29256978)
5. Holland WL, Summers SA (2008) Sphingolipids, insulin resistance, and metabolic disease: New insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev 29, 381-402. (Pubitemid 351831506)
6. Langeveld M, Aerts JM (2009) Glycosphingolipids and insulin resistance. Prog Lipid Res 48, 196-250.
7. Kraegen EW, Cooney GJ (2008) Free fatty acids and skeletal muscle insulin resistance. Curr Opin Lipidol 19, 235-241. (Pubitemid 351653560)
8. Liu B, Obeid LM, Hannun YA (1997) Sphingomyelinases in cell regulation. Semin Cell Dev Biol 8, 311-322. (Pubitemid 127346646)
9. Reynolds CP, Maurer BJ, Kolesnick RN (2004) Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 206, 169-180. (Pubitemid 38317287)
10. Summers SA (2006) Ceramides in insulin resistance and lipo-toxicity. Prog Lipid Res 45, 42-72.
11. Cowart LA (2009) Sphingolipids: Players in the pathology of metabolic disease. Trends Endocrinol Metab 20, 34-42.
12. Hannun YA, Obeid LM (2008) Principles of bioactive lipid signalling: Lessons from sphingolipids. Nat Rev Mol Cell Biol 9, 139-150. (Pubitemid 351158911)
13. Ruvolo PP (2003) Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol Res 47, 383-392. (Pubitemid 36379200)
14. Bourbon NA, Sandirasegarane L, Kester M (2002) Ceramide-induced inhibition of Akt is mediated through protein kinase Czeta: Implications for growth arrest. J Biol Chem 277, 3286-3292. (Pubitemid 34953194)
15. Hajduch E, Balendran A, Batty IH, Litherland GJ, Blair AS, Downes CP, Hundal HS (2001) Ceramide impairs the insulin-dependent membrane recruitment of protein kinase B leading to a loss in downstream signalling in L6 skeletal muscle cells. Diabetologia 44, 173-183. (Pubitemid 32156201)
16. Nogueira TC, Anhe GF, Carvalho CR, Curi R, Bordin S, Carpinelli AR (2008) Involvement of phosphatidylinositol-3 kinase/AKT/PKCzeta/lambda pathway in the effect of palmitate on glucose-induced insulin secretion. Pancreas 37, 309-315.
17. Powell DJ, Hajduch E, Kular G, Hundal HS (2003) Ceramide disables 3-phosphoinositide binding to the pleck-strin homology domain of protein kinase B (PKB) /Akt by a PKCzeta-dependent mechanism. Mol Cell Biol 23, 7794-7808. (Pubitemid 37271476)
18. Chavez JA, Knotts TA, Wang LP, Li G, Dobrowsky RT, Florant GL, Summers SA (2003) A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction bysaturated fatty acids. J Biol Chem278, 10297-10303. (Pubitemid 36800291)
19. Stratford S, Hoehn KL, Liu F, Summers SA (2004) Regulation of insulin action by ceramide: Dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J Biol Chem 279, 36608-36615. (Pubitemid 39129005)
20. Anderson N, Borlak J (2008) Molecular mechanisms and therapeutic targets insteatosis and steatohepatitis. Pharmacol Rev 60, 311-357.
21. Kaplowitz N, Than TA, Shinohara M, Ji C (2007) Endoplas-mic reticulum stress and liver injury. Semin Liver Dis 27, 367-377. (Pubitemid 350071837)
22. Malhi H, Gores GJ (2008) Molecular mechanisms of lipotox-icity in nonalcoholic fatty liver disease. Semin Liver Dis 28, 360-369.
23. Sundar Rajan S, Srinivasan V, Balasubramanyam M, Tatu U (2007) Endoplasmic reticulum (ER) stress & diabetes. Indian J Med Res 125, 411-424. (Pubitemid 46805455)
24. Hotamisligil GS (2010) Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 140, 900-917.
25. Malhi H, Kaufman RJ (2011) Endoplasmic reticulum stress in liver disease. J Hepatol 54, 795-809.
26. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gorgun C, Glimcher LH, Hotamisligil GS (2004) Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306, 457-461. (Pubitemid 39372439)
27. Dara L, Ji C, Kaplowitz N (2011) The contribution of endo-plasmic reticulum stress to liver diseases. Hepatology 53, 1752-1763.
28. Braak H, Braak E (1997) Staging of Alzheimer-related cortical destruction. Int Pychogeriatr 9 (Suppl 1) , 257-261; discussion 269-272.
29. Nagy Z, Esiri MM, Joachim C, Jobst KA, Morris JH, King EM, Hindley NJ, McDonald B, Litchfield S, Barnetson L, Smith AD (1998) Comparison of pathological diagnostic cri- teria for Alzheimer disease. Alzheimer Dis Assoc Disords 12, 182-189.
30. Lyn-Cook LE Jr, Lawton M, Tong M, Silbermann E, Lon-gato L, Jiao P, Mark P, Wands JR, Xu H, de la Monte SM (2009) Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis. J Alzheimers Dis 16, 715-729.
31. Moroz N, Tong M, Longato L, Xu H, de la Monte SM (2008) Limited Alzheimer-type neurodegeneration in experimental obesity and Type 2 diabetes mellitus. J Alzheimers Dis 15, 29-44.
32. Promrat K, Longato L, Wands JR, de la Monte SM (2011) Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels. Hepatol Res 41, 754-762.
33. Tu BP, Weissman JS (2004) Oxidative protein folding in eukaryotes: Mechanisms and consequences. J Cell Biol 164, 341-346. (Pubitemid 38174761)
34. Kny M, Standera S, Hartmann-Petersen R, Kloetzel PM, Seeger M (2011) Herp regulates Hrd1-mediated ubiquity-lation in a ubiquitin-like domain-dependent manner. J Biol Chem 286, 5151-5156.
35. van Huizen R, Martindale JL, Gorospe M, Holbrook NJ (2003) P58IPK, a novel endoplasmic reticulum stress-inducible protein and potential negative regulator of eIF2alpha signaling. J Biol Chem 278, 15558-15564. (Pubitemid 36799663)
36. Gottfries CG, Karlsson I, Svennerholm L (1996) Membrane components separate early-onset Alzheimer's disease from senile dementia of the Alzheimer type. Int Psychogeriatr 8, 365-372. (Pubitemid 27067586)
37. He X, Huang Y, Li B, Gong CX, Schuchman EH (2010) Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging 31, 398-408.
38. Haughey NJ, Bandaru VV, Bae M, Mattson MP (2010) Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Biochim Biophys Acta 1801, 878-886.
39. Han X (2010) Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer's disease. Biochim Biophys Acta 1801, 774-783.
40. Han X, M Holtzman D, McKeel DW Jr, Kelley J, Morris JC (2002) Substantialsulfatide deficiency and ceramide elevation in very early Alzheimer's disease: Potential role in disease pathogenesis. J Neurochem 82, 809-818.
41. Marks N, Berg MJ, Saito M (2008) Glucosylceramide syn-thase decrease in frontal cortex of Alzheimer brain correlates with abnormal increase in endogenous ceramides: Consequences to morphology and viability on enzyme suppression in cultured primary neurons. Brain Res 1191, 136-147.
42. Katsel P, Li C, Haroutunian V (2007) Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: A shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease? Neurochem Res 32, 845-856. (Pubitemid 46481322)
43. Hejazi L, Wong JW, Cheng D, Proschogo N, Ebrahimi D, Gar-ner B, Don AS (2011) Mass and relative elution time profiling: Two-dimensional analysis of sphingolipids in Alzheimer's disease brains. Biochemical J 438, 165-175.
44. Grosgen S, Grimm MO, Friess P, Hartmann T (2010) Role of amyloid beta in lipid homeostasis. Biochim Biophys Acta 1801, 966-974.
45. Ait-Ghezala G, Abdullah L, Crescentini R, Crawford F, Town T, Singh S, Richards D, Duara R, Mullan M (2002) Confirma- tionofassociation between D10S583 and Alzheimer's disease in a case-control sample. Neurosci Lett 325, 87-90. (Pubitemid 34614536)
46. Martins IJ, Hone E, Foster JK, Sunram-Lea SI, Gnjec A, Fuller SJ, Nolan D, Gandy SE, Martins RN (2006) Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 11, 721-736. (Pubitemid 44141805)
47. Bandaru VV, Troncoso J, Wheeler D, Pletnikova O, Wang J, Conant K, Haughey NJ (2009) ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. Neurobiol Aging 30, 591-599.
48. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM (2006) Intracerebral streptozotocin model of type 3 diabetes: Relevance to sporadic Alzheimer's disease. J Alzheimers Dis 9, 13-33.
49. de la Monte SM, Tong M, Lawton M, Longato L (2009) Nitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment. Mol Neurode-gener 4, 54.
50. Tong M, Longato L, de la Monte SM (2010) Early limited nitrosamine exposures exacerbate high fat diet-mediated type2 diabetes and neurodegeneration. BMC Endocr Disord 10, 4.
51. de la Monte SM, Wands JR (2008) Alzheimer's disease is type 3 diabetes: Evidence reviewed. J Diabetes Sci Tech 2, 1101-1113.
52. Hoyer S, Muller D, Plaschke K (1994) Desensitization of brain insulin receptor effect on glucose/energy and related metabolism. J Neural Transm Suppl 44, 259-268. (Pubitemid 24372903)
53. Hoyer S (2000) Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease causes and consequences: An update. Exp Gerontol 35, 1363-1372.
54. Craft S (2007) Insulin resistance and Alzheimer's disease pathogenesis: Potential mechanisms and implications for treatment. Curr Alzheimer Res 4, 147-152. (Pubitemid 46557503)
55. Chang RC, Wong AK, Ng HK, Hugon J (2002) Phospho-rylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal degenerationinAlzheimer's disease. Neuroreport 13, 2429-2432. (Pubitemid 36143538)
56. Hoozemans JJ, van Haastert ES, Nijholt DA, Rozemuller AJ, Eikelenboom P, Scheper W (2009) The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus. Am J Pathol 174, 1241-1251.
57. Morel M, Couturier J, Lafay-Chebassier C, Paccalin M, Page G (2009) PKR, the double stranded RNA-dependent protein kinase as a critical target in Alzheimer's disease. J Cell Mol Med 13, 1476-1488.
58. Tuppo EE, Arias HR (2005) The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 37, 289-305. (Pubitemid 39330191)
59. Dheen ST, Kaur C, Ling EA (2007) Microglial activation and its implications in the brain diseases. Curr Med Chem 14, 1189-1197. (Pubitemid 46739320)